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ABSTRACT: A copper-mediated conjugate addition of electron-
rich aryl groups into a complex vinyl nitrile using arylmagnesium
bromides is reported. The conjugate addition adducts were
advanced toward the synthesis of designed aconitine-type ana-
logues. The variation in oxygenation patterns on the arene
coupling partner, introduced through the current conjugate addi-
tion approach, may ultimately provide insight into structure−
activity relationships of the diterpenoid alkaloids.
Aconitine (1, Figure 1) and lappaconitine (2) elicit contrastingeffects upon interaction with human voltage-gated sodium
ion channels; aconitine exposure induces persistent activation
of neurons leading to cardiac arrest, whereas lappaconitine
leads to blockage of acute pain signals.1,2 These two related
diterpenoid alkaloids exemplify the disparate effects of this
class of natural products on voltage-gated ion channels.3−6
Given that voltage-gated sodium (NaV), calcium (CaV), and
potassium (KV) ion channels regulate biophysical responses
across the nervous, circulatory, and muscular systems, the
ability to selectively target voltage-gated sodium ion channels
would have significant implications for the treatment of
epilepsy, chronic pain, and myriad other channelopathies.7
Diterpenoid alkaloids have long been recognized for their
utility in combating channelopathies, appearing in traditional
Chinese medicine as treatments for pain and cardiovascular
disease.6 Today, lappaconitine (3) is approved and marketed
in China and Russia for pain relief and arrhythmia treatment,8
effects which likely stem from lappaconitine blocking NaV
channels.9 On the other hand, aconitine (1) is a highly toxic NaV
channel activator reported to be lethal to humans in doses as low
as 1−2 mg.10 Talatisamine (2) is a known KV channel blocker,
whereas chasmanine (4) has no known ion channel activity.4,11
The pronounced biological effects of small changes to the
periphery of these pseudoalkaloids have made the structural
origin of their bioactivities a matter of interest for over a
century. Among the first to explore the structure−activity
relationships (SAR) of the diterpenoid alkaloids were Cash and
Dunstan, who compared aconitine to two hydrolyzed deriv-
atives, aconine and 14-O-benzoylaconine.12 More recently,
Tursunkhodzhaeva and co-workers probed these relationships
with a larger set of isolated diterpenoid alkaloids and their
derivatives.13,14 This approach led to the identification of some
key substituents on aconitine-type and lappaconitine-type natu-
ral products that imbue them with certain biological activities,
but this study was limited by its inability to systematically vary
the peripheral substituents. Not all combinations of sub-
stitution patterns are present in the known diterpenoid
alkaloids and derivatization has been limited to hydrolysis of
amides and to acylationor, in one case, methylationof free
hydroxy groups. Furthermore, lack of site selectivity for
acylation in the presence of multiple hydroxy groups has
limited the synthesis of derivatives.
Our lab has developed strategies to access several C18-, C19-,
and C20-diterpenoid alkaloids.
15−17 While these efforts yielded
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Figure 1. Selected examples of diterpenoid alkaloids.
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enough material for biological assays, the syntheses are
relatively long and opportunities for wide-ranging introduction
of oxygenation have been limited. In order to overcome these
challenges, we explored a synthesis approach to aconitine-type
analogues that should be more amenable to systematic vari-
ation of oxygenation patterns. In designing these analogues, we
generated a set of key considerations on the basis of which
structural features are conserved and which are varied across
this family of natural products (Figure 2).
Previous SAR studies have indicated that variation in hydroxy-
lation along the D ring has a drastic impact on the biological
activity of aconitine-type diterpenoid alkaloids.13,14 The pri-
mary emphasis of our design strategy thus focuses on varying
the substitution pattern around this ring, while maintaining
selected features common to the aconitine-type natural prod-
ucts. To this end, our analogues were designed to retain the
A−E−F ring carbon framework, whichunlike the [3.2.1]
bicycle comprised by the C and D ringsis conserved across
the majority of the atisane-derived alkaloids. The N-ethyl
group and the C1 methoxy group are also highly conserved
within this family and thus maintained in our designs for
analogues. C4 substituents, however, differ greatly between
aconitine- and lappaconitine-type diterpenoid alkaloids. To facili-
tate a thorough exploration of the importance of the D ring
substitution patterns, the C4 substituents were excluded from
our present study, although these C4 substituents may be
incorporated at a later stage using previously established
strategies.17 Additionally, diterpenoid alkaloids bearing a
[2.2.2] bicycle as their CD ring system, a change which
significantly alters the conformation of the D ring compared to
that of the aconitine system, are also known to modulate ion
channels.18 Therefore, our initial studies aimed to excise C12
as this structural simplification would allow more rapid access
to natural product-inspired analogues that probe the
tolerability of the binding site to modulations in polarity,
shape and spatial orientation in the D ring.
On the basis of these considerations, we targeted analogues,
such as pentacycle 5 and spirocycle 6 (Figure 3). Each of these
designed targets could ultimately arise from aldehyde 7 through
oxidative dearomatization strategies. Aldehyde 7, in turn, could
be taken back to primary amide 8, which itself could be derived
from known vinyl nitrile 9.15 In the forward sense, this route
would begin with a conjugate addition of aryl nucleophiles into
9. Additional analogues could be accessed through variation of
the nucleophile in this step, resulting in differing oxygenation
patterns on the aryl ring (see Table 1) prior to oxidative
dearomatization.
Our initial approach toward these simplified analogues was
to effect a Hayashi-type19 Rh-catalyzed conjugate addition of
boronate esters into vinyl nitrile 9, following previously suc-
cessful protocols from our laboratories. However, this reaction
proved to be sensitive to the electronics and substitution
patterns of the arene nucleophiles. While the Rh-catalyzed
method worked well for the two previously published sub-
strates (Table 1, 10a and 10b), the same was not true when
the boronate derived from MOM-protected p-bromophenol
was used (see 10d, Method A). In the latter case, low
conversion (67% recovery of nitrile 9) was observed.
To address the poor reactivity of many substituted aryl
boronate esters in the Rh(I)-catalyzed conjugate addition, we
investigated an organocuprate-based strategy using copper(I)
iodide and Grignard reagents (Method B). While the condi-
tions that were initially selected followed related precedent
involving addition of alkyl cuprates into simpleand often
highly activatedvinyl nitriles,20−23 high yields using structurally
complex vinyl nitrile 9 were only realized after extensive
Figure 2. Ring labeling and analogue design considerations.
Figure 3. Retrosynthesis of two classes of aconitine analogues.
Table 1. Scope and Comparison of Rh-Catalyzed and
Cu-Mediated Methods for Conjugate Addition
aProcedure taken from previous report; see ref 17. bSmall amounts of
β-CN diastereomer obtained but not characterized.
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optimization. Our Cu-mediated conjugate addition method pro-
ceeded under milder conditions than the Rh-catalyzed approach
and gave the desired product (10d) with improved efficiency
over the Rh-catalyzed conjugate addition conditions (see 10d,
Method A). While a mixture of diastereomers were obtained
(2.8:1 d.r. at C17), the undesired β-isomer could be readily
epimerized using base to the desired α-isomer (vide infra).
In order to facilitate syntheses of analogues related to 5 and 6
with a variety of substitution patterns, we explored a series of
Cu-mediated conjugate additions using various oxygenated
arenes. The reaction proved to be robust, tolerating a variety
of substitution patterns, including sterically hindered arenes.
While the use of o,m-disubstituted arenes (10a) resulted in low
conversion, the reaction proceeded in good to excellent yield
when other doubly oxygenated arenes with at least one
o-substituent were used (10c, 10f, 10m). The conjugate
addition also accommodated various phenols masked as MOM
ethers (10d, 10g, 10j). Additionally, the method worked in the
presence of a dibromoarene (see 10i), allowing one of the
bromine atoms to be preserved as a functional handle for further
derivatization.
The conjugate addition products could then be elaborated to
the caged scaffold conserved between the bioactive diterpenoid
alkaloids. A synthesis of aldehyde 7 (Scheme 1) is illustrative of
our approach to the common aldehyde intermediates required
to generate aconitine-type analogues. Starting from vinyl nitrile
9, conjugate addition of the cuprate derived from arylmagne-
sium bromide 11 afforded 10d as a mixture of diastereomers,
which were separated by flash column chromatography.
The minor β-CN product (β-10d) was converted to the
desired α-CN diastereomer (α-10d) under basic conditions.
The structure of nitrile β-10d and the configuration of the two
newly installed stereocenters relative to the rest of the
hydrindane system were unambiguously confirmed by X-ray
crystallography.
At this stage, the ester moiety of α-10d was reduced with
Red-Al and the resultant alcohol was protected as a MOM
ether to give 12. This allowed us to retain the hydroxy group as
a functional handle, in contrast to our previous syntheses,
where the primary alcohol was converted to a terminal
olefin.15−17 The nitrile group was then hydrated under
anhydrous conditions to afford primary amide 8. A Hofmann
rearrangement of this amide afforded a primary amine, which
was subsequently acetylated to form an acetamide. In previous
syntheses, a methyl carbamate had instead been installed on
related substrates at this stage. This necessitated late-stage
conversion of that carbamate into an acetamide. Strategies
to do so required hydrolysis and decarboxylation, which
generally required harsh reaction conditions. We surmised that
the severe conditions for these steps would likely be pro-
blematic in the current synthesis due to the presence of free
hydroxy groups in our late-stage intermediates. Thus, given
that we would eventually require an acetamidethat would
ultimately be reduced to the ethylamine present in our
designed analogueswe decided to convert amide 8 directly
to an acetamide. Following acetylation, TBAF-mediated
cleavage of the TBS group gave alcohol 13. Mesylation of
the primary hydroxy group in 13 set the stage for cyclization to
form piperidine 14 under basic conditions, completing the
caged left-hand side of the molecule. The two MOM groups on
14 were then cleaved and the newly revealed primary
hydroxy group was oxidized under Swern conditions to give
aldehyde 7.
The exploration of various cyclization modes of key
intermediate 7 to the aconitine-type analogues is ongoing in
our laboratories. Preliminary studies toward the spirocyclic
analogues are particularly promising, and the desired scaffold
(15) is formed through oxidative dearomatization with
PhI(OAc)2 in the presence of methanol (Scheme 2).
31 Efforts
toward intermolecular oxidative dearomatization en route to
the BD-fused analogues are also underway.
In summary, with a route to aldehyde 7 firmly established
through our development of a robust and versatile conju-
gate addition protocol, the stage is now set for the explora-
tion of aconitine-type analogues related to BD-fused 5 and
spirocyclic 6, which may provide additional insight into the
structure−activity relationship of these intriguing pseudoalka-
loids.
Scheme 1. Formation of Caged Piperidine Skeleton
aSubstituents on the silicon atom omitted for clarity in CYLView rendering of the crystal structure of β-10d.
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■ EXPERIMENTAL SECTION
General Experimental Methods. 1. Solvents and Reagents.
Unless noted below, commercial reagents were used without addi-
tional purification. Tetrahydrofuran (THF), diethyl ether (Et2O),
acetonitrile (MeCN), benzene, methanol (MeOH), and triethylamine
(Et3N) were sparged with argon and dried by passing through
alumina columns using argon in a Glass Contour solvent purification
system. Dichloromethane (CH2Cl2) was freshly distilled over calcium
hydride under a N2 atmosphere prior to each use. DMSO and toluene
(PhMe) were distilled over calcium hydride under a N2 atmosphere,
degassed using freeze−pump−thaw (3 cycles), and stored over 4 Å
molecular sieves in a Schlenk flask under N2. Dimethylformamide
(DMF), acetone, n-BuLi solution, LiHMDS solution, Red-Al solution,
Grignard solutions, and pyridine were purchased in Sure-Seal,
AcroSeal, or ChemSeal bottling, and used directly. 1,4-Dioxane was
purchased in AcroSeal bottling (99.5%, anhydrous, stabilized, over
4 Å molecular sieves) and additionally sparged with N2 prior to use.
2. Reaction Setup, Progress Monitoring, and Product Purifica-
tion. Unless otherwise noted in the experimental procedures, reactions
were carried out in flame or oven-dried glassware under a positive
pressure of N2 in anhydrous solvents using standard Schlenk tech-
niques. Reactions run at temperatures above rt (22−23 °C) were
controlled by an IKA temperature modulator and monitored using
liquid-in-glass thermometers. Reaction progress was monitored using
a combination of LC/MS analysis (Shimadzu LC−MS-2020 (UFLC)
equipped with the LC20AD solvent delivery system, a SPD-20AV
prominence UV−vis detector (SPD-M20A Photo Diode Array), and a
Thermo Scientific Hypersil GOLD HPLC column (5 μm particle size,
4.6 × 50 mm)) and thin-layer chromatography (TLC) on EMD
Millipore silica gel plates (glass backed, extra hard layer, 60 Å, 250 μm
thickness, F254 indicator). Visualization of the developed plates was
performed under UV-light (254 nm) irradiation, and subsequent gentle
heating with KMnO4, p-anisaldehyde, or ceric ammonium molybdate
stains. Purification and isolation of products were performed via silica
gel chromatography (both column and preparative thin-layer chro-
matography). Flash column chromatography was performed with
either glass columns using Fisherbrand silica gel (40−63 μm particle
size) or with a Yamazen Smart S4 Flash EPCLC W-Prep 2XY (dual
channel) automated flash chromatography system on prefilled,
premium, universal columns using ACS grade solvents. Organic
solutions were concentrated under reduced pressure on a Heidolph
temperature-controlled rotary evaporator equipped with a dry ice/
isopropanol condenser or a Büchi temperature-controlled rotary evapo-
rator equipped with an Ecodyst Ecochyll system.
3. Analytical Instrumentation. NMR spectral data were obtained
using deuterated solvents obtained from Cambridge Isotope Labo-
ratories, Inc. 1H NMR and 13C NMR data were recorded on Bruker
AVB-400, AVQ-400, AV-500, DRX-500, AV-600, or AV-700 MHz
spectrometers using CDCl3, CD3OD, or C6D6, typically at 20−23 °C.
Chemical shifts (δ) are reported in ppm relative to the residual
solvent signal (δ 7.26 for 1H NMR, δ 77.16 for 13C NMR in
CDCl3).
24 Data for 1H NMR spectroscopy are reported as follows;
chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t =
triplet, q = quartet, p = pentet, m = multiplet, bs = broad singlet, dd =
doublet of doublets, dt = doublet of triplets, dq = doublet of quartets,
ddd = doublet of doublets of doublets, dtd = doublet of triplets of
doublets, dtt = doublet of triplets of triplets, ddq = doublet of doublets
of quartets, dddd = doublet of doublets of doublets of doublets, td =
triplet of doublets, tt = triplet of triplets, tdd = triplet of doublets of
doublets, qd = quartet of doublets, qt = quartet of triplets), coupling
constant (Hz), integration. Data for 13C NMR spectroscopy are
reported in terms of chemical shift (δ ppm). IR spectroscopic data
were recorded on a Bruker ALPHA FT-IR spectrophotometer using a
diamond attenuated total reflectance (ATR) accessory. Samples are
loaded onto the diamond surface either neat or as a solution in organic
solvent and the data acquired after the solvent had evaporated. Mass
spectral data were obtained from the Mass Spectral Facility at the
University of California, Berkeley, on a Finnigan/Thermo LTQ-FT
instrument (ESI), or from the Catalysis Facility of Lawrence Berkeley
National Laboratory (supported by US Department of Energy under
contract no. DE-AC02-05CH11231), on a PerkinElmer AxION 2
UHPLC-TOF system (ESI or APCI). Data acquisition and processing
were performed using the Xcalibur software. X-ray data were collected
on a Bruker APEX-II CCD diffractometer with Mo Kα radiation (λ =
0.71073 Å) or a MicroStar-H X8 APEX-II diffractometer with Cu Kα
radiation (λ = 1.54178 Å) (University of California, Berkeley; Supported
by an NIH Shared Instrumentation Grant S10- RR027172). CYLview
and ORTEP3 were used for graphic rendering.25,26
Synthesis of Aryl Bromides for Conjugate Additions in
Table 1. 1-Bromo-4-(methoxymethoxy)benzene (S1). 4-Bromophe-
nol (25.2 g, 145 mmol, 1.0 equiv) and K2CO3 (30.2 g, 218 mmol,
1.5 equiv) were dissolved in acetone (200 mL, 0.67 M) at room tem-
perature. To this stirring suspension was added MOMCl (16.5 mL,
218 mmol, 1.5 equiv) dropwise over 5 min. The reaction mixture was
then heated in an oil bath at 60 °C for 20 h. The reaction mixture was
then cooled to room temperature and concentrated in vacuo to remove
acetone. The resultant wet solid was dissolved in water (75 mL), then
extracted with Et2O (3 × 75 mL). The combined organic extracts
were washed with brine (25 mL), dried over MgSO4, and concen-
trated in vacuo. Purification by column chromatography eluting with
0−10% EtOAc in hexanes gave S1 as a colorless oil (26.3 g,
121 mmol, 83%). 1H NMR (400 MHz, CDCl3) δ 7.38 (m, 2H), 6.92
(m, 2H), 5.15 (s, 2H), 3.47 (s, 3H). Spectroscopic data for this
compound were identical to those previously reported.27
1-Bromo-3-(methoxymethoxy)benzene (S2). 3-Bromophenol
(1.37 g, 8.00 mmol, 1.0 equiv) and K2CO3 (1.66 g, 12.0 mmol,
1.5 equiv) were dissolved in acetone (12.0 mL, 0.67 M) at room tem-
perature. To this stirring suspension was added MOMCl (0.91 mL,
12.0 mmol, 1.5 equiv) dropwise over 5 min. The reaction mixture was
then heated in an oil bath at 60 °C for 16 h. The reaction mixture was
then cooled to room temperature and concentrated in vacuo to remove
acetone. The resultant wet solid was dissolved in water (10 mL), then
extracted with Et2O (3 × 10 mL). The combined organic extracts
were washed with brine (5 mL), dried over MgSO4, and concentrated
in vacuo. Purification by column chromatography eluting with 0−7%
EtOAc in hexanes gave S2 as a colorless oil (879 mg, 4.05 mmol,
51%). 1H NMR (600 MHz, CDCl3) δ 7.22 (t, J = 1.7 Hz, 1H),
7.18−7.08 (m, 2H), 6.97 (dt, J = 6.6, 2.5 Hz, 1H), 5.16 (s, 2H), 3.47
(s, 3H). Spectroscopic data for this compound were identical to those
previously reported.28
1-Bromo-2-(methoxymethoxy)benzene (S3). 2-Bromophenol
(1.38 g, 8.00 mmol, 1.0 equiv) and K2CO3 (1.67 g, 12.0 mmol,
1.5 equiv) were dissolved in acetone (12.0 mL, 0.67 M) at room tem-
perature. To this stirring suspension was added MOMCl (0.91 mL,
12.0 mmol, 1.5 equiv) dropwise over 5 min. The reaction mixture was
then heated in an oil bath at 60 °C for 16 h. The reaction mixture
was then cooled to room temperature and concentrated in vacuo
to remove acetone. The resultant wet solid was dissolved in water
(10 mL), then extracted with Et2O (3 × 10 mL). The combined
organic extracts were washed with brine (5 mL), dried over MgSO4,
and concentrated in vacuo. Purification by column chromatography
eluting with 0−7% EtOAc in hexanes gave S3 as a colorless oil
(1.13 g, 5.21 mmol, 65%). 1H NMR (600 MHz, CDCl3) δ 7.55
(dd, J = 7.9, 1.6 Hz, 1H), 7.25 (td, J = 7.6, 1.6 Hz, 1H), 7.15 (dd, J =
8.3, 1.5 Hz, 1H), 6.89 (td, J = 7.6, 1.5 Hz, 1H), 5.25 (s, 2H), 3.53
(s, 3H). Spectroscopic data for this compound were identical to those
previously reported.29
1,3-Dibromo-5-(methoxymethoxy)benzene (S4). 3,5-Dibromo-
phenol (1.37 g, 5.44 mmol, 1.0 equiv) and K2CO3 (1.18 g,
8.16 mmol, 1.5 equiv) were dissolved in acetone (8.0 mL, 0.67 M)
Scheme 2. Oxidative Dearomatization of 7 To Build
Spirocyclic Scaffold
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at room temperature. To this stirring suspension was added MOMCl
(0.41 mL, 8.16 mmol, 1.5 equiv) dropwise over 5 min. The reaction
mixture was then heated in an oil bath at 60 °C for 16 h. The reaction
mixture was then cooled to room temperature and concentrated
in vacuo to remove acetone. The resultant wet solid was dissolved in
water (5 mL), then extracted with Et2O (3 × 5 mL). The combined
organic extracts were washed with brine (5 mL), dried over MgSO4,
and concentrated in vacuo. Purification by column chromatography
eluting with 0−7% EtOAc in hexanes gave S4 as a colorless oil
(1.17 g, 3.95 mmol, 73%). 1H NMR (600 MHz, CDCl3) δ 7.30 (t, J =
1.6 Hz, 1H), 7.15 (d, J = 1.6 Hz, 2H), 5.14 (s, 2H), 3.47 (s, 3H).
Spectroscopic data for this compound were identical to those pre-
viously reported.30
General Procedure for Copper Conjugate Additions Using
Aryl Bromides (Method 1). Aryl bromide (0.527 mmol, 4.0 equiv)
and magnesium (14.0 mg, 0.580 mmol, 4.4 equiv) were dissolved in
THF (1 mL, 0.53 M with respect to aryl bromide) and heated in an
oil bath at 50 °C for 45 min or until the magnesium turnings had
mostly dissolved. The reaction mixture was then allowed to cool to
room temperature and then placed in an ice/water bath. The solution
was then transferred via syringe to a chilled vial containing copper(I)
iodide (50.0 mg, 0.263 mmol, 2.0 equiv) and stirred vigorously in the
ice bath for 25 min. At this point, vinyl nitrile 9 (50.0 mg, 0.132 mmol,
1.0 equiv) was added as a solution in THF (0.5 mL, 0.26 M). The
reaction mixture was removed from the ice bath, sealed with a Teflon
cap, and heated in an oil bath at 45 °C and held at this temperature
for 20 h. The reaction mixture was then allowed to cool to room
temperature, quenched with MeOH (0.25 mL), diluted with NH4Cl
(saturated aqueous, 5 mL), and extracted with EtOAc (3 × 5 mL).
The combined organic extracts were washed with brine (3 × 2 mL),
dried over Na2SO4, and concentrated in vacuo.
General Procedure for Copper Conjugate Additions Using
Commercial Grignard Reagents (Method 2). Commercial
Grignard solution (0.527 mmol, 4.0 equiv) was diluted to 0.53 M
in THF in a sealed 1 dram vial under N2 and cooled in an ice/water
bath. The solution was then transferred via syringe to a chilled vial
containing copper(I) iodide (50.0 mg, 0.263 mmol, 2.0 equiv) and
stirred vigorously in the ice bath for 25 min. At this point, vinyl nitrile
9 (50.0 mg, 0.132 mmol, 1.0 equiv) was added as a solution in THF
(0.5 mL, 0.26 M). The reaction mixture was removed from the ice
bath, sealed with a Teflon cap, and heated in an oil bath at 45 °C for
20 h. The reaction mixture was then allowed to cool to room tem-
perature, quenched with MeOH (0.25 mL), diluted with NH4Cl
(saturated aqueous, 5 mL), and extracted with EtOAc (3 × 5 mL).
The combined organic extracts were washed with brine (3 × 2 mL),
dried over Na2SO4, and concentrated in vacuo.
2-Methoxy-3-OMOM Tricycle (10a). Prepared according to
method 1. Purification by column chromatography (eluting with
60−100% CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided
α-10a (trace amounts) as a colorless oil in <5% yield. 1H NMR
(600 MHz, CDCl3) δ 7.03 (dd, J = 8.1, 1.2 Hz, 1H), 6.97 (t, J =
7.9 Hz, 1H), 6.88 (dd, J = 7.7, 1.1 Hz, 1H), 5.23−5.18 (m, 2H), 4.04
(ddd, J = 11.6, 8.7, 2.9 Hz, 1H), 3.98 (s, 1 H), 3.94 (s, 3H), 3.74
(s, 3H), 3.52 (s, 3H), 3.44 (s, 3H), 3.40 (dd, J = 7.4, 2.3 Hz, 2H),
3.25 (d, J = 8.4 Hz, 1H), 3.11 (ddd, J = 13.3, 9.0, 4.9 Hz, 1H), 2.40
(q, J = 12.5 Hz, 1H), 2.09 (ddd, J = 13.8, 4.9, 2.2 Hz, 1H), 2.00 (dtt, J =
11.8, 7.4, 4.5 Hz, 1H), 1.63 (ddd, J = 12.3, 9.1, 3.0 Hz, 1H), 1.47−1.32
(m, 3H), 0.88 (s, 9H), 0.02 (s, 3H), −0.01 (s, 3H). Spectroscopic data
for this compound were identical to those previously reported.15
3,5-Dimethoxy Tricycle (10b). Prepared according to method 1.
Run with modified equivalents of reagents (6.0 equiv of Grignard
solution, 5.0 equiv of CuI). Purification by column chromatography
(eluting with 60−100% CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2)
provided α-10b and β-10b in 76% combined yield.
α-10b. Isolated as a colorless oil (37.1 mg, 0.0717 mmol, 58%).
1H NMR (500 MHz, CDCl3) δ 6.42 (d, J = 2.2 Hz, 2H), 6.33
(t, J = 2.2 Hz, 1H), 3.97 (bs, 1H), 3.79 (s, 6H), 3.73 (s, 3H), 3.68
(ddd, J = 11.4, 8.4, 2.8 Hz, 1H), 3.43 (s, 3H), 3.42 (s, 1H), 3.41
(s, 1H), 3.08 (d, J = 8.4 Hz, 1H), 3.00 (ddd, J = 13.6, 8.9, 4.8 Hz,
1H), 2.41 (q, J = 12.6 Hz, 1H), 2.12−2.06 (m, 1H), 2.02−1.95
(m, 1H), 1.74 (ddd, J = 12.4, 9.0, 2.9 Hz, 1H), 1.50−1.27 (m, 3H),
0.88 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H). Spectroscopic data for this
compound were identical to those previously reported.15
β-10b. Isolated as a pale yellow oil (11.6 mg, 0.0224 mmol, 18%).
1H NMR (600 MHz, CDCl3) δ 6.43 (d, J = 2.2 Hz, 2H), 6.34 (t, J =
2.2 Hz, 1H), 3.92 (s, 1H), 3.82−3.77 (m, 1H), 3.78 (s, 6H), 3.78
(s, 3H), 3.64 (d, J = 9.7 Hz, 1H), 3.49 (dd, J = 9.8, 7.4 Hz, 1H), 3.43
(dd, J = 9.9, 7.3 Hz, 1H), 3.37 (s, 3H), 3.22 (ddd, J = 13.6, 8.9,
5.3 Hz, 1H), 2.28 (td, J = 13.0, 11.5 Hz, 1H), 2.15 (tdd, J = 12.0, 7.3,
4.7 Hz, 1H), 2.07 (dq, J = 14.4, 3.0 Hz, 1H), 1.86 (ddd, J = 12.5, 9.0,
3.1 Hz, 1H), 1.41−1.34 (m, 1H), 1.31 (qd, J = 13.1, 2.9 Hz, 1H), 1.19
(dddd, J = 14.9, 13.3, 3.7, 1.8 Hz, 1H), 0.90 (s, 9H), 0.06 (s, 3H),
0.04 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.7, 160.9, 145.0,
119.2, 106.7, 99.1, 79.6, 66.6, 63.1, 57.3, 55.4, 53.0, 46.1, 44.8, 41.4,
38.1, 32.3, 26.1, 25.4, 18.4, 16.4, −5.2; IR (thin film) 2950, 2930,
2900, 2856, 2237, 1738, 1596, 1460, 1250, 1205, 1153, 1105, 1085,
835, 775 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for
C28H43O6NNaSi 540.2752; found 540.2743.
2,5-Dimethoxy Tricycle (10c). Prepared according to method 1.
Purification by column chromatography (eluting with 60−100%
CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided α-10c and
β-10c in 93% combined yield.
α-10c. Isolated as a colorless oil (44.3 mg, 0.0856 mmol, 28%).
1H NMR (600 MHz, CDCl3) δ 6.78 (d, J = 8.8 Hz, 1H), 6.77 (d, J =
3.0 Hz, 1H), 6.73 (dd, J = 8.8, 3.0 Hz, 1H), 3.97 (q, J = 1.8 Hz, 1H),
3.87 (ddd, J = 11.9, 8.7, 3.2 Hz, 1H), 3.79 (s, 3H), 3.76 (s, 3H), 3.74
(s, 3H), 3.44 (s, 3H), 3.42 (d, J = 8.7 Hz, 1H), 3.41−3.38 (m, 2H),
3.16 (ddd, J = 13.3, 9.1, 4.9 Hz, 1H), 2.31 (q, J = 12.3 Hz, 1H),
2.09 (dq, J = 14.0, 3.0 Hz, 1H), 1.96 (tt, J = 11.5, 3.8 Hz, 1H), 1.71
(ddd, J = 12.4, 9.1, 3.3 Hz, 1H), 1.47−1.32 (m, 3H), 0.88 (s, 9H),
0.02 (s, 3H), 0.01 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 173.6,
153.7, 151.5, 133.5, 120.6, 116.0, 112.2, 111.9, 77.2, 66.6, 60.6, 57.0,
55.9, 55.9, 52.8, 46.1, 44.0, 42.7, 38.4, 32.1, 26.1, 25.0, 18.4, 16.8,
−5.3; IR (thin film) 2950, 2931, 2896, 2856, 2237, 1728, 1501, 1248,
1223, 1101, 1080, 1048, 835, 775 cm−1; HRMS (ESI) m/z [M + Na]+
calc’d for C28H43O6NNaSi 540.2752, found 540.2749.
β-10c. Isolated as a colorless oil (19.3 mg, 0.0372 mmol, 65%).
1H NMR (600 MHz, CDCl3) δ 6.87 (d, J = 3.0 Hz, 1H), 6.78 (d, J =
8.8 Hz, 1H), 6.74 (dd, J = 8.8, 2.9 Hz, 1H), 4.12 (ddd, J = 11.4, 9.9,
2.9 Hz, 1H), 3.91 (p, J = 1.5 Hz, 1H), 3.80 (s, 3H), 3.79−3.75 (m, 1H),
3.76 (s, 3H), 3.75 (s, 3H), 3.54 (dd, J = 9.9, 7.0 Hz, 1H), 3.45
(dd, J = 9.9, 7.5 Hz, 1H), 3.39 (s, 3H), 3.17 (ddd, J = 13.5, 8.4,
4.9 Hz, 1H), 2.21 (td, J = 13.1, 11.2 Hz, 1H), 2.12 (tdd, J = 12.0, 7.3,
4.8 Hz, 1H), 2.07 (dq, J = 14.7, 3.3 Hz, 1H), 1.93 (ddd, J = 12.3, 8.7,
3.1 Hz, 1H), 1.42−1.29 (m, 2H), 1.19 (tdd, J = 14.7, 4.2, 2.0 Hz, 1H),
0.91 (s, 9H), 0.07 (s, 3H), 0.07 (s, 3H); 13C NMR (151 MHz,
CDCl3) δ 172.9, 153.7, 151.8, 131.9, 119.4, 115.0, 111.9, 111.2, 79.8,
66.8, 62.9, 57.5, 56.0, 55.9, 52.9, 43.8, 41.1, 39.4, 38.2, 29.7, 26.1,
25.6, 18.5, 16.6, −5.2; IR (thin film) 2952, 2928, 2855, 2234, 1739,
1591, 1496, 1250, 1219, 1106, 1087, 1054, 837, 776 cm−1; HRMS
(ESI) m/z [M + Na]+ calc’d for C28H43O6NNaSi 540.2752, found
540.2747.
4-OMOM Tricycle (10d). Prepared according to method 1. Puri-
fication by column chromatography (eluting with 60−100% CH2Cl2/
hexanes, then 1−5% Et2O/CH2Cl2) provided α-10d and β-10d in
90% combined yield from 1.23 g (3.24 mmol) of nitrile 9.
α-10d. Isolated as a colorless oil (1.10 g, 2.13 mmol, 66%).
1H NMR (500 MHz, CDCl3) δ 7.20−7.17 (m, 2H), 7.00−6.96
(m, 2H), 5.21−4.93 (m, 2H), 3.97 (bs, 1H), 3.73 (s, 3H), 3.70
(ddd, J = 11.4, 8.3, 2.7 Hz, 1H), 3.47 (s, 3H), 3.45−3.37 (m, 2H),
3.43 (s, 3H), 3.03 (ddd, J = 13.5, 9.1, 4.5 Hz, 1H), 3.02 (d, J = 8.4 Hz,
1H), 2.43 (td, J = 13.1, 11.5 Hz, 1H), 2.09 (dq, J = 12.9, 2.7 Hz, 1H),
2.00 (dtd, J = 10.7, 6.2, 3.5 Hz, 1H), 1.72 (ddd, J = 12.4, 9.0,
2.9 Hz, 1H), 1.47−1.32 (m, 3H), 0.89 (s, 9H), 0.03 (s, 3H), 0.01
(s, 3H); 13C NMR (126 MHz, CDCl3) δ 173.3, 156.2, 139.1, 128.0,
120.1, 116.8, 94.6, 77.1, 66.2, 60.4, 57.1, 56.1, 52.9, 48.7, 47.8, 43.4,
38.2, 33.1, 26.0, 24.8, 18.4, 16.6, −5.26, −5.29; IR (thin film) 2951,
2929, 2897, 2856, 2240, 1731, 1511, 1462, 1237, 1079, 1005, 815,
776 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for C28H43O6NNaSi
540.2752, found 540.2757.
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β-10d. Isolated as a colorless oil, which slowly solidified overnight
at rt (394 mg, 0.761 mmol, 24%). 1H NMR (600 MHz, CDCl3)
δ 7.19 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 5.16 (qd, J = 6.8,
1.2 Hz, 2H), 3.92 (bs, 1H), 3.83−3.76 (m, 1H), 3.78 (s, 3H), 3.64
(d, J = 9.7 Hz, 1H), 3.49−3.41 (m, 2H), 3.74 (s, 3H) 3.37 (s, 3H),
3.25 (ddd, J = 13.6, 8.8, 5.4 Hz, 1H), 2.32 (q, J = 12.8 Hz, 1H), 2.15
(qd, J = 12.1, 6.7 Hz, 1H), 2.07 (dt, J = 14.6, 3.4 Hz, 1H), 1.82
(ddd, J = 12.4, 8.8, 2.8 Hz, 1H), 1.39−1.16 (m, 3H), 0.91 (s, 9H),
0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.8,
156.4, 136.4, 129.5, 119.3, 116.3, 94.6, 79.6, 66.5, 63.1, 57.3, 56.1,
53.0, 45.1, 44.9, 41.4, 38.0, 32.9, 26.1, 25.4, 18.4, 16.4, −5.22, −5.24;
IR (thin film) 2951, 2929, 2856, 2233, 1739, 1512, 1462, 1248, 1153,
1103, 1006, 836, 776 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for
C28H43O6NNaSi 540.2752, found 540.2756.
α-10d from β-10d. β-10d (366.9 mg, 0.709 mmol, 1.0 equiv) and
K2CO3 (147.0 mg, 1.06 mmol, 1.5 equiv) were dissolved in MeOH
(7.0 mL, 0.1 M) and heated in an oil bath at 80 °C for 1 h. The
reaction mixture was allowed to cool to room temperature, at which
time it was quenched with NH4Cl (saturated aqueous, 5 mL), concen-
trated in vacuo to remove MeOH, and then extracted with CH2Cl2
(3 × 4 mL). The combined organic extracts were washed with brine
(2 mL), dried over Na2SO4, and concentrated in vacuo to give a
yellow oil. Purification by column chromatography (eluting with
5−35% EtOAc/hexanes) provided α-10d as a colorless oil (321.2 mg,
0.620 mmol, 88%).
4-Methoxy Tricycle (10e). Prepared according to method 2. Run
with modified equivalents of reagents (6.0 equiv of Grignard solution,
5.0 equiv of CuI). Purification by column chromatography (eluting
with 60−100% CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided
α-10e and β-10e in 88% combined yield.
α-10e. Isolated as a colorless oil (37.7 mg, 0.0773 mmol, 59%).
1H NMR (500 MHz, CDCl3) δ 7.22 (d, J = 8.7 Hz, 2H), 6.87 (d, J =
8.6 Hz, 2H), 4.00 (bs, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.72 (ddd, J =
11.3, 8.4, 2.9 Hz, 1H), 3.46 (s, 3H), 3.49−3.39 (m, 2H), 3.07
(ddd, J = 13.3, 8.7, 4.8 Hz, 1H), 3.05 (d, J = 8.4 Hz, 1H), 2.47 (td, J =
12.9, 11.7 Hz, 1H), 2.12 (dq, J = 12.7, 2.6 Hz, 1H), 2.03 (qd, J = 7.2,
2.7 Hz, 1H), 1.75 (ddd, J = 12.2, 8.9, 2.9 Hz, 1H), 1.52−1.31
(m, 3H), 0.93 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H).; 13C NMR
(126 MHz, CDCl3) δ 173.3, 158.5, 137.8, 127.9, 120.1, 114.3, 77.0,
66.1, 57.0, 55.4, 52.8, 48.6, 47.8, 43.3, 38.1, 33.1, 26.0, 24.8, 18.3,
16.5, −5.3, −5.4; IR (thin film) 2948, 2928, 2855, 2238, 1736, 1612,
1514, 1435, 1250, 1106, 1077, 834, 809, 778 cm−1; HRMS (ESI) m/z
[M + Na]+ calc’d for C27H41O5NNaSi 510.2646, found 510.2648.
β-10e. Isolated as a pale yellow oil (18.7 mg, 0.0383 mmol, 29%).
1H NMR (500 MHz, CDCl3) δ 7.23−7.13 (m, 2H), 6.92−6.67
(m, 2H), 3.91 (bs, 1H), 3.83−3.75 (m, 1H), 3.79 (s, 3H), 3.78
(s, 3H), 3.64 (d, J = 9.7 Hz, 1H), 3.46 (d, J = 7.4 Hz, 2H), 3.37
(s, 3H), 3.26 (ddd, J = 13.6, 8.8, 4.9 Hz, 1H), 2.33 (td, J = 13.1,
11.0 Hz, 1H), 2.15 (tdd, J = 12.3, 7.4, 4.9 Hz, 1H), 2.07 (dq, J = 14.9,
3.4 Hz, 1H), 1.82 (ddd, J = 12.3, 8.8, 3.0 Hz, 1H), 1.38−1.24
(m, 2H), 1.19 (dddd, J = 14.4, 12.2, 4.8, 2.0 Hz, 1H), 0.92 (s, 9H),
0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.8,
158.6, 135.1, 129.4, 119.4, 114.0, 79.6, 66.5, 63.1, 57.3, 55.3, 53.0,
45.03, 44.98, 41.4, 38.0, 32.9, 26.1, 25.4, 18.4, 16.4, −5.22, −5.24;
IR (thin film) 2950, 2930, 2899, 2856, 2234, 1738, 1612, 1514, 1462,
1249, 1179, 1102, 1085, 835, 775 cm−1; HRMS (ESI) m/z [M + Na]+
calc’d for C27H41O5NNaSi 510.2646, found 510.2645.
2,4-Dimethoxy Tricycle (10f). Prepared according to method 1.
Purification by column chromatography (eluting with 60−100%
CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided α-10f and
β-10f in 82% combined yield.
α-10f. Isolated as a colorless oil (35.3 mg, 0.0682 mmol, 52%).
1H NMR (600 MHz, CDCl3) δ 7.08 (d, J = 8.3 Hz, 1H), 6.44 (d, J =
2.4 Hz, 1H), 6.40 (dd, J = 8.3, 2.4 Hz, 1H), 3.97 (bs, 1H), 3.84
(td, J = 8.6, 4.3 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 3H), 3.73 (s, 3H), 3.43
(s, 3H), 3.40 (d, J = 7.4 Hz, 2H), 3.35 (d, J = 8.5 Hz, 1H), 3.16
(ddd, J = 13.3, 9.0, 5.0 Hz, 1H), 2.29 (q, J = 12.3 Hz, 1H), 2.08
(ddd, J = 12.4, 5.2, 2.2 Hz, 1H), 1.96 (tdd, J = 11.7, 7.5, 4.7 Hz, 1H),
1.70 (ddd, J = 12.3, 9.0, 3.2 Hz, 1H), 1.46−1.28 (m, 3H), 0.88
(s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); 13C NMR (151 MHz, CDCl3)
δ 173.7, 160.1, 158.2, 129.8, 124.9, 120.8, 104.1, 99.2, 77.3, 66.5, 60.5,
57.0, 55.5, 55.3, 52.7, 45.6, 44.2, 42.6, 38.4, 31.9, 26.1, 25.0, 18.4,
16.8, −5.3; IR (thin film) 2950, 2930, 2892, 2856, 2237, 1730, 1613,
1507, 1463, 1257, 1209, 1102, 1083, 1038, 836, 776 cm−1; HRMS
(ESI) m/z [M + Na]+ calc’d for C28H43O6NNaSi 540.2752, found
540.2762.
β-10f. Isolated as a colorless oil (20.7 mg, 0.0400 mmol, 30%).
1H NMR (600 MHz, CDCl3) δ 7.20 (d, J = 8.3 Hz, 1H), 6.46 (dd, J =
8.3, 2.4 Hz, 1H), 6.44 (d, J = 2.4 Hz, 1H), 4.05 (ddd, J = 11.8, 9.8,
2.8 Hz, 1H), 3.90 (p, J = 1.4 Hz, 1H), 3.82 (s, 3H), 3.79 (s, 3H),
3.75 (s, 3H), 3.74 (d, J = 9.8 Hz, 1H), 3.53−3.44 (m, 2H), 3.38
(s, 3H), 3.21 (ddd, J = 13.5, 8.4, 5.6 Hz, 1H), 2.22 (td, J = 13.1,
11.1 Hz, 1H), 2.12 (ddd, J = 14.4, 7.1, 1.9 Hz, 1H), 2.06 (dq, J = 14.5,
3.2 Hz, 1H), 1.93 (ddd, J = 12.8, 8.5, 2.8 Hz, 1H), 1.36−1.31
(m, 2H), 1.18 (dtd, J = 16.9, 6.0, 1.9 Hz, 1H), 0.93 (s, 9H), 0.08 (s,
3H), 0.07 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 173.0, 159.9,
158.4, 128.2, 123.3, 119.7, 104.2, 98.7, 79.8, 66.7, 62.8, 57.5, 55.5,
55.4, 52.9, 43.9, 41.1, 38.5, 38.1, 29.9, 26.1, 25.6, 18.5, 16.6, −5.2;
IR (thin film) 2952, 2933, 2904, 2856, 2238, 1739, 1613, 1587, 1464,
1290, 1252, 1103, 1085, 836, 776 cm−1; HRMS (ESI) m/z [M + Na]+
calc’d for C28H43O6NNaSi 540.2752, found 540.2748.
3-OMOM Tricycle (10g). Prepared according to method 1.
Purification by column chromatography (eluting with 60−100%
CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided α-10g and
β-10g in 98% combined yield.
α-10g. Isolated as a colorless oil (46.2 mg, 0.0892 mmol, 68%).
1H NMR (600 MHz, CDCl3) δ 7.25−7.21 (m, 1H), 6.92 (s, 2H),
6.91 (d, J = 2.1 Hz, 1H), 5.19 (d, J = 6.8 Hz, 1H), 5.15 (d, J = 6.8 Hz,
1H), 3.97 (p, J = 1.3 Hz, 1H), 3.74 (s, 3H), 3.71 (ddd, J = 11.4,
8.4, 2.9 Hz, 1H), 3.48 (s, 3H), 3.45−3.38 (m, 2H), 3.43 (s, 3H), 3.08
(d, J = 8.4 Hz, 1H), 3.03 (ddd, J = 13.6, 9.0, 4.9 Hz, 1H), 2.44 (td, J =
13.0, 11.5 Hz, 1H), 2.09 (dq, J = 13.8, 2.4 Hz, 1H), 2.00 (dtd, J =
16.1, 7.4, 4.9 Hz, 1H), 1.74 (ddd, J = 12.3, 9.0, 2.8 Hz, 1H),
1.49−1.30 (m, 3H), 0.89 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H);
13C NMR (151 MHz, CDCl3) δ 173.3, 157.8, 147.3, 130.2, 120.2,
112.0, 115.5, 114.3, 94.6, 77.1, 66.2, 60.5, 57.1, 56.2, 52.9, 49.3, 47.4,
43.4, 38.2, 33.0, 26.0, 24.8, 18.3, 16.6, −5.27, −5.30; IR (thin film)
2953, 2929, 2897, 2855, 2240, 1731, 1584, 1462, 1452, 1249, 1150,
1078, 1020, 981, 834, 774 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d
for C28H43O6NNaSi 540.2752, found 540.2749.
β-10g. Isolated as a colorless oil (20.8 mg, 0.0402 mmol, 30%).
1H NMR (600 MHz, CDCl3) δ 7.25−7.21 (m, 1H), 6.95 (dt, J =
7.7, 1.2 Hz, 1H), 6.92 (ddd, J = 5.2, 2.7, 1.7 Hz, 2H), 5.17 (s, 2H),
3.92 (t, J = 2.5 Hz, 1H), 3.81 (ddd, J = 11.8, 9.9, 2.9 Hz, 1H), 3.78
(s, 3H), 3.66 (d, J = 9.7 Hz, 1H), 3.50−3.43 (m, 2H), 3.48 (s, 3H),
3.37 (s, 3H), 3.24 (ddd, J = 13.6, 9.1, 5.2 Hz, 1H), 2.31 (td, J =
13.1, 11.0 Hz, 1H), 2.15 (dtd, J = 12.0, 7.3, 3.7 Hz, 1H), 2.07 (dq, J =
14.5, 3.3 Hz, 1H), 1.86 (ddd, J = 12.4, 8.9, 3.0 Hz, 1H), 1.40−1.28
(m, 2H), 1.19 (dddd, J = 14.9, 13.1, 4.2, 2.0 Hz, 1H), 0.91 (s, 9H),
0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.7,
157.4, 144.6, 129.7, 121.8, 119.1, 116.8, 114.8, 94.7, 79.6, 66.5, 63.1,
57.3, 56.1, 53.0, 45.8, 44.8, 41.5, 38.1, 32.5, 26.1, 25.4, 18.4, 16.4,
−5.23, −5.24; IR (thin film) 2951, 2928, 2898, 2856, 2238, 1739,
1609, 1585, 1462, 1249, 1151, 1080, 1025, 1009, 835, 775, 729 cm−1;
HRMS (ESI) m/z [M + Na]+ calc’d for C28H43O6NNaSi 540.2752,
found 540.2752.
3-Methoxy Tricycle (10h). Prepared according to method 2. Puri-
fication by column chromatography (eluting with 60−100% CH2Cl2/
hexanes, then 1−5% Et2O/CH2Cl2) provided α-10h and β-10h in
92% combined yield from 1.26 mmol of nitrile 9.
α-10h. Isolated as a colorless oil (430 mg, 0.882 mmol, 70%).
1H NMR (600 MHz, CDCl3) δ 7.24 (t, J = 7.9 Hz, 1H), 6.87 (dt, J =
7.6, 1.2 Hz, 1H), 6.81 (t, J = 2.1 Hz, 1H), 6.77 (ddd, J = 8.2, 2.6,
0.9 Hz, 1H), 3.97 (bs, 1H), 3.81 (s, 3H), 3.73 (s, 3H), 3.71 (ddd, J =
11.3, 8.4, 2.9 Hz, 1H), 3.43 (s, 3H), 3.47−3.37 (m, 2H), 3.08
(d, J = 8.3 Hz, 1H), 3.03 (ddd, J = 13.6, 8.9, 4.8 Hz, 1H), 2.44 (td, J =
13.1, 11.6 Hz, 1H), 2.09 (dq, J = 14.1, 3.1 Hz, 1H), 2.00 (dtd, J =
16.0, 7.5, 4.9 Hz, 1H), 1.76 (ddd, J = 12.3, 9.0, 2.8 Hz, 1H),
1.48−1.33 (m, 3H), 0.89 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H);
13C NMR (151 MHz, CDCl3) δ 173.3, 160.1, 147.3, 130.1, 120.0,
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119.1, 113.0, 112.2, 77.1, 66.3, 60.5, 57.1, 55.4, 52.9, 49.4, 47.5,
43.4, 38.2, 33.0, 26.0, 24.8, 18.4, 16.6, −5.26, −5.28; IR (thin film)
2951, 2929, 2897, 2857, 2239, 1732, 1600, 1463, 1255, 1119,
1084, 1051, 837, 777 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for
C27H41O5NNaSi 510.2646, found 510.2647.
β-10h. Isolated as a colorless oil (132 mg, 0.271 mmol, 22%).
1H NMR (600 MHz, CDCl3) δ 7.24 (d, J = 7.9 Hz, 1H), 6.88 (dt, J =
7.5, 1.2 Hz, 1H), 6.80 (t, J = 2.1 Hz, 1H), 6.78 (ddd, J = 8.2, 2.6,
0.9 Hz, 1H), 3.92 (bs, 1H), 3.85−3.78 (m, 1H), 3.80 (s, 3H), 3.78
(s, 3H), 3.66 (d, J = 9.8 Hz, 1H), 3.46 (qd, J = 9.9, 7.4 Hz, 2H), 3.37
(s, 3H), 3.25 (ddd, J = 13.6, 8.9, 5.0 Hz, 1H), 2.31 (td, J = 13.1,
11.0 Hz, 1H), 2.15 (tdd, J = 12.3, 7.6, 4.9 Hz, 1H), 2.08 (dq, J = 14.1,
2.9 Hz, 1H), 1.87 (ddd, J = 12.4, 8.8, 3.0 Hz, 1H), 1.39−1.35
(m, 1H), 1.31 (qd, J = 12.9, 3.0 Hz, 1H), 1.20 (dddd, J = 14.8, 12.8,
4.0, 2.0 Hz, 1H), 0.91 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H); 13C NMR
(151 MHz, CDCl3) δ 172.7, 159.7, 144.5, 129.6, 120.7, 119.2, 114.6,
112.4, 79.6, 66.6, 63.1, 57.3, 55.3, 53.0, 45.9, 44.8, 41.5, 38.1, 32.5,
26.1, 25.4, 18.4, 16.4, −5.2; IR (thin film) 2951, 2930, 2856,
2359, 1737, 1602, 1462, 1422, 1257, 1230, 1105, 1086, 1053,
837, 813, 803,778 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for
C27H41O5NNaSi 510.2646, found 510.2639.
3-Bromo-5-OMOM Tricycle (10i). Prepared according to method 1.
Purification by column chromatography (eluting with 60−100%
CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided 10i (39.8 mg,
0.0667 mmol) as an inseparable mixture of diastereomers (2.3:1
α:β-10i) in 49% combined yield. IR (thin film) 2953, 2930, 2895,
2857, 2241, 1732, 1602, 1568, 1462, 1451, 1437, 1256, 1152, 1083,
1026, 1007, 838, 776 cm−1; HRMS (APCI) m/z [M + H]+ calc’d for
C28H43
81BrNO6Si 598.2017, found 598.2020.
α-10i. 1H NMR (600 MHz, CDCl3) δ 7.10 (dd, J = 2.3, 1.7 Hz,
1H), 7.04 (t, J = 1.6 Hz, 1H), 6.85 (t, J = 1.9 Hz, 1H), 5.17 (d, J =
6.9 Hz, 1H), 5.12 (d, J = 6.9 Hz, 1H), 3.98−3.95 (m, 1H), 3.75
(s, 3H), 3.67 (ddd, J = 11.5, 8.5, 3.0 Hz, 1H), 3.47 (s, 3H), 3.47−3.44
(m, 1H), 3.42 (s, 3H), 3.40−3.33 (m, 1H), 3.04 (d, J = 8.5 Hz, 1H),
3.00 (ddd, J = 13.3, 8.9, 4.9 Hz, 1H), 2.48−2.37 (m, 1H), 2.09
(dq, J = 13.8, 3.0 Hz, 1H), 2.03−1.98 (m, 1H), 1.71 (ddd, J = 12.4,
9.0, 2.9 Hz, 1H), 1.48−1.41 (m, 1H), 1.34 (tt, J = 10.7, 3.5 Hz, 2H),
0.90 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H); 13C NMR (151 MHz,
CDCl3) δ 173.1, 158.4, 148.8, 123.1, 120.2, 119.7, 117.8, 114.7, 94.6,
77.0, 66.1, 60.4, 57.1, 56.3, 53.0, 49.1, 47.2, 43.2, 38.1, 32.9, 26.1,
24.8, 18.4, 16.5, −5.25, −5.28.
β-10i. 1H NMR (600 MHz, CDCl3) δ 7.23 (tdd, J = 7.3, 2.0,
0.8 Hz, 1H), 6.92 (s, 1H), 6.91 (d, J = 2.4 Hz, 1H), 5.20 (d, J =
6.8 Hz, 1H), 5.15 (d, J = 6.8 Hz, 1H), 3.98−3.95 (m, 1H), 3.74
(s, 3H), 3.71 (ddd, J = 11.5, 8.6, 3.0 Hz, 1H), 3.48 (s, 3H), 3.47−3.44
(m, 1H), 3.43 (s, 3H), 3.40−3.33 (m, 1H), 3.08 (d, J = 8.3 Hz, 1H),
3.00 (ddd, J = 13.3, 8.9, 4.9 Hz, 1H), 2.48−2.37 (m, 1H), 2.09
(dq, J = 13.8, 3.0 Hz, 1H), 2.03−1.98 (m, 1H), 1.74 (ddd, J =
12.4, 9.0, 2.9 Hz, 1H), 1.48−1.41 (m, 1H), 1.37 (tt, J = 10.7, 3.5 Hz,
2H), 0.89 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); 13C NMR (151 MHz,
CDCl3) δ 173.3, 157.8, 147.4, 130.2, 123.4, 120.0, 115.5, 114.3, 94.6,
77.1, 66.2, 60.5, 57.1, 56.2, 52.9, 49.3, 47.4, 43.4, 38.2, 33.1, 26.0,
24.8, 18.4, 16.6, −5.26, −5.29.
2-OMOM Tricycle (10j). Prepared according to method 1.
Purification by column chromatography (eluting with 60−100%
CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided α-10j and
β-10j in 76% combined yield.
α-10j. Isolated as a colorless oil (36.3 mg, 0.0701 mmol, 53%).
1H NMR (600 MHz, CDCl3) δ 7.22 (dd, J = 7.6, 1.7 Hz, 1H), 7.19
(ddd, J = 8.2, 7.3, 1.7 Hz, 1H), 7.11 (dd, J = 8.3, 1.2 Hz, 1H),
6.95 (td, J = 7.4, 1.2 Hz, 1H), 5.25 (d, J = 6.9 Hz, 1H), 5.23 (d, J =
6.9 Hz, 1H), 4.01 (ddd, J = 11.6, 8.6, 3.0 Hz, 1H), 3.99 (dd, J =
3.2, 1.6 Hz, 1H), 3.72 (s, 3H), 3.50 (s, 3H), 3.45 (s, 3H), 3.42 (d, J =
7.3 Hz, 2H), 3.30 (d, J = 8.4 Hz, 1H), 3.15 (ddd, J = 13.4, 8.8, 4.9 Hz,
1H), 2.38 (q, J = 12.4 Hz, 1H), 2.13−2.07 (m, 1H), 1.98 (dq, J =
12.1, 5.9 Hz, 1H), 1.76 (ddd, J = 12.2, 8.9, 3.0 Hz, 1H), 1.48−1.32
(m, 3H), 0.89 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR
(151 MHz, CDCl3) δ 173.6, 155.0, 133.2, 128.8, 128.3, 122.1, 120.5,
114.2, 94.4, 77.2, 66.6, 60.6, 57.0, 56.3, 52.8, 44.79, 44.76, 43.0, 38.4,
32.0, 26.0, 25.0, 18.4, 16.8, −5.2, −5.3; IR (thin film) 2952, 2929,
2895, 2856, 2239, 1728, 1492, 1471, 1249, 1077, 1000, 835, 775,
753 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for C28H43O6NNaSi
540.2752, found 540.2748.
β-10j. Isolated as a colorless oil (15.5 mg, 0.0299 mmol, 23%).
1H NMR (600 MHz, CDCl3) δ 7.33 (dd, J = 7.7, 1.6 Hz, 1H), 7.21
(ddd, J = 8.2, 7.4, 1.7 Hz, 1H), 7.10 (dd, J = 8.3, 1.2 Hz, 1H),
7.00 (td, J = 7.5, 1.2 Hz, 1H), 5.25 (d, J = 6.6 Hz, 1H), 5.20
(d, J = 6.6 Hz, 1H), 4.17 (td, J = 11.2, 2.7 Hz, 1H), 3.93 (p, J = 1.3
Hz, 1H), 3.78 (d, J = 9.8 Hz, 1H), 3.75 (s, 3H), 3.52 (s, 3H),
3.54−3.47 (m, 2H), 3.40 (s, 3H), 3.23 (ddd, J = 13.5, 8.5, 4.9 Hz,
1H), 2.26 (td, J = 13.2, 11.1 Hz, 1H), 2.18−2.09 (m, 1H), 2.08
(dq, J = 14.4, 3.1 Hz, 1H), 1.99 (ddd, J = 12.1, 8.4, 2.7 Hz, 1H),
1.39−1.30 (m, 2H), 1.20 (ddd, J = 17.1, 10.4, 4.3 Hz, 1H), 0.93
(s, 9H), 0.08 (s, 3H), 0.07 (s, 3H); 13C NMR (151 MHz, CDCl3)
δ 172.9, 155.4, 131.4, 128.4, 127.8, 122.0, 119.4, 114.0, 95.0, 79.8,
66.7, 62.9, 57.4, 56.3, 52.9, 43.7, 41.3, 38.9, 38.1, 29.9, 26.1, 25.5,
18.5, 16.6, −5.18, −5.20; IR (thin film) 2951, 2928, 2896, 2855, 2236,
1739, 1492, 1457, 1249, 1231, 1082, 1003, 836, 776, 754 cm−1;
HRMS (ESI) m/z [M + Na]+ calc’d for C28H43O6NNaSi 540.2752,
found 540.2746.
2-Methoxy Tricycle (10k). Prepared according to method 2.
Purification by column chromatography (eluting with 60−100%
CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided α-10k and
β-10k in 57% combined yield from 200 mg (0.527 mmol) of nitrile 9.
α-10k. Isolated as a colorless oil (110. mg, 0.223 mmol, 42%).
1H NMR (600 MHz, CDCl3) δ 7.22 (td, J = 7.6, 1.7 Hz, 1H), 7.19
(dd, J = 7.6, 1.6 Hz, 1H), 6.89 (td, J = 7.5, 1.0 Hz, 1H), 6.86 (d, J =
8.2 Hz, 1H), 3.97 (t, J = 2.1 Hz, 1H), 3.92 (ddd, J = 11.7, 8.5, 3.1 Hz,
1H), 3.84 (s, 3H), 3.73 (s, 3H), 3.44 (s, 3H), 3.41 (dd, J = 7.4,
1.3 Hz, 2H), 3.38 (d, J = 8.5 Hz, 1H), 3.18 (ddd, J = 13.3, 8.9, 4.9 Hz,
1H), 2.32 (q, J = 12.3 Hz, 1H), 2.09 (dq, J = 12.4, 2.5 Hz, 1H), 1.97
(dtt, J = 11.8, 7.6, 4.5 Hz, 1H), 1.75 (ddd, J = 12.3, 9.0, 3.2 Hz, 1H),
1.46−1.31 (m, 3H), 0.88 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); 13C
NMR (151 MHz, CDCl3) δ 173.7, 157.3, 132.4, 129.3,
128.3, 120.8, 120.7, 111.0, 77.3, 66.5, 60.6, 57.0, 55.3, 52.8, 45.7,
44.1, 42.7, 38.3, 31.8, 26.0, 25.0, 18.4, 16.8, −5.2; IR (thin film) 2951,
2930, 2856, 2239, 1730, 1601, 1494, 1462, 1247, 1102, 1082,
837, 776, 753 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for
C27H41O5NNaSi 510.2646, found 510.2653.
β-10k. Isolated as a colorless oil (37.7 mg, 0.0773 mmol, 15%).
1H NMR (600 MHz, CDCl3) δ 7.31 (dd, J = 7.7, 1.6 Hz, 1H), 7.23
(ddd, J = 8.2, 7.4, 1.7 Hz, 1H), 6.95 (td, J = 7.5, 1.1 Hz, 1H), 6.87
(dd, J = 8.2, 1.1 Hz, 1H), 4.13 (ddd, J = 11.4, 9.7, 2.7 Hz, 1H), 3.92
(t, J = 2.9 Hz, 1H), 3.85 (s, 3H), 3.78 (d, J = 9.7 Hz, 1H), 3.75
(s, 3H), 3.54−3.46 (m, 2H), 3.40 (s, 3H), 3.23 (ddd, J = 13.5, 8.5,
4.9 Hz, 1H), 2.24 (td, J = 13.1, 11.0 Hz, 1H), 2.13 (dt, J = 14.0,
7.4 Hz, 1H), 2.07 (dq, J = 14.5, 3.3 Hz, 1H), 1.99 (ddd, J = 12.2, 8.5,
2.8 Hz, 1H), 1.37−1.30 (m, 2H), 1.23−1.15 (m, 1H), 0.93 (s, 9H),
0.08 (s, 3H), 0.07 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.8,
157.3, 130.6, 128.1, 127.5, 120.5, 119.3, 110.3, 79.6, 66.5, 62.6, 57.3,
55.3, 52.7, 43.5, 41.0, 38.8, 37.9, 29.5, 25.9, 25.4, 18.3, 16.4, −5.38,
−5.39; IR (thin film) 2950, 2930, 2857, 2235, 1740, 1494, 1463,
1244, 1103, 1086, 1056, 1033, 837, 776, 752 cm−1; HRMS (ESI) m/z
[M + Na]+ calc’d for C27H41O5NNaSi 510.2646, found 510.2641.
2,6-Dimethoxy Tricycle (10m). Prepared according to method 1.
Purification by column chromatography (eluting with 60−100%
CH2Cl2/hexanes, then 1−5% Et2O/CH2Cl2) provided α-10m as a
single diastereomer (52.4 mg, 0.101 mmol, 83%). 1H NMR (600 MHz,
CDCl3) δ 7.16 (t, J = 8.3 Hz, 1H), 6.54 (d, J = 8.3 Hz, 2H), 4.48
(ddd, J = 11.9, 10.2, 3.5 Hz, 1H), 3.90 (t, J = 2.5 Hz, 1H), 3.80
(s, 6H), 3.79 (s, 3H), 3.56−3.43 (m, 3H), 3.40 (s, 3H), 3.35 (dd, J =
9.9, 7.9 Hz, 1H), 2.14−1.98 (m, 3H), 1.91 (ddd, J = 12.2, 9.2, 3.5 Hz,
1H), 1.40 (dq, J = 11.6, 3.6 Hz, 1H), 1.32 (qd, J = 13.1, 3.0 Hz, 1H),
1.18 (tdd, J = 13.5, 3.8, 1.9 Hz, 1H), 0.89 (s, 9H), 0.04 (s, 3H),
0.03 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 173.1, 158.9, 128.3,
120.30, 118.5, 104.3, 80.2, 67.2, 63.5, 57.5, 55.7, 52.8, 43.1, 40.9,
38.6, 34.8, 31.0, 26.1, 25.8, 18.5, 16.9, −5.17, −5.22; IR (thin film)
2951, 2931, 2895, 2856, 2237, 1739, 1594, 1474, 1594, 1474, 1249,
1102, 838, 775 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for
C28H43O6NNaSi 540.2752, found 540.2746.
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Synthesis of Dienone 15 from Ester α-10d. Alcohol Derived
from Ester α-10d (S5). Ester α-10d (1.732 g, 3.34 mmol, 1.0 equiv)
was dissolved in CH2Cl2 (33 mL, 0.1 M) and cooled in an ice/water
bath. Red-Al solution (3.4 mL, 11.7 mmol, 3.5 equiv, 70 wt % in
PhMe) was added dropwise over 5 min. The reaction mixture was
stirred in the bath for 1 h, then allowed to warm gradually to room
temperature over 2.25 h. The reaction mixture was then diluted with
THF (25 mL), at which point it was cooled in an ice/water bath again
and quenched by the serial addition of H2O (88 μL), NaOH
(2.0 M aqueous, 88 μL), and H2O (3 × 88 μL). The reaction mixture
was allowed to warm gradually to room temperature over 12 h, then
filtered over a plug of Celite, which was rinsed with THF (25 mL),
then EtOAc (50 mL). The combined organic filtrates were con-
centrated in vacuo to give a colorless oil. Purification by column chro-
matography (eluting with 17−37% EtOAc/hexanes) provided alcohol S5
as a clear gum (1.365 g, 2.79 mmol, 83%). 1H NMR (700 MHz,
C6D6) δ 7.21 (dd, J = 8.2, 1.2 Hz, 2H), 7.05 (dd, J = 8.7, 1.0 Hz, 2H),
4.86 (qd, J = 6.9, 1.0 Hz, 2H), 3.80 (ddd, J = 11.4, 8.4, 2.7 Hz, 1H),
3.33 (dd, J = 14.8, 7.0 Hz, 1H), 3.32 (dd, J = 14.8, 7.0 Hz, 1H), 3.28
(s, 3H), 3.24 (d, J = 11.1 Hz, 1H), 3.20 (s, 1H), 3.15 (s, 3H), 3.06
(d, J = 8.5 Hz, 1H), 2.52 (ddd, J = 13.4, 8.6, 4.7 Hz, 1H), 2.39
(q, J = 12.4 Hz, 1H), 1.79−1.71 (m, 2H), 1.70 (dq, J = 14.8, 3.1 Hz,
1H), 1.63 (ddd, J = 12.2, 8.7, 2.7 Hz, 1H), 1.34 (qd, J = 13.4, 3.4 Hz,
1H), 1.22 (dd, J = 13.3, 3.5 Hz, 1H), 1.01 (tt, J = 12.9, 2.3 Hz, 1H),
0.97 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); 13C NMR (176 MHz, C6D6)
δ 156.7, 140.5, 128.3, 121.5, 117.0, 94.5, 78.0, 66.8, 63.5, 56.9,
55.8, 55.5, 48.2, 45.8, 39.7, 37.8, 34.3, 26.1, 24.3, 18.5, 17.4, −5.3;
IR (thin film) 3474, 2952, 2929, 2890, 2857, 2234, 1511, 1250, 1088,
1007, 836, 776 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d for
C27H43NNaO5Si 512.2803, found 512.2806.
MOM Ether 12. Alcohol S5 (2.60 g, 5.30 mmol, 1.0 equiv) was
dissolved in PhMe (26 mL, 0.2 M) in a round-bottomed flask. DIPEA
(3.70 mL, 21.2 mmol, 4.0 equiv) was added to the stirring mixture,
followed by MOMCl (1.60 mL, 21.2 mmol, 4.0 equiv). The flask was
fitted with a reflux condenser and heated in an oil bath at 70 °C for
12 h. The reaction mixture was then allowed to cool to room tem-
perature, at which point it was quenched by the addition of NaHCO3
(saturated aqueous, 20 mL) and extracted with EtOAc (3 × 10 mL).
The combined organic extracts were washed with brine (10 mL),
dried over Na2SO4, filtered, and concentrated in vacuo to provide
MOM ether 12 as an orange oil (2.84 g, 5.30 mmol, >99% crude
yield), which was advanced without further purification. 1H NMR
(500 MHz, C6D6) δ 7.22 (d, J = 8.7 Hz, 2H), 7.05 (d, J = 8.7 Hz,
2H), 4.91−4.69 (m, 2H), 4.30 (bs, 2H), 3.83 (ddd, J = 11.4, 8.4,
2.7 Hz, 1H), 3.34−3.29 (m, 1H), 3.30 (s, 3H), 3.31−3.25 (m, 3H),
3.21 (d, J = 9.9 Hz, 1H), 3.13 (s, 3H), 3.12 (s, 1H), 3.10 (s, 3H), 2.57
(ddd, J = 13.4, 8.6, 4.8 Hz, 1H), 2.39 (q, J = 12.3 Hz, 1H), 1.76
(qt, J = 7.3, 3.6 Hz, 1H), 1.71−1.63 (m, 1H), 1.66 (t, J = 3.7 Hz, 1H),
1.33 (qd, J = 13.0, 2.4 Hz, 1H), 1.14 (dd, J = 13.4, 3.5 Hz, 1H),
1.08−0.97 (m, 1H), 0.95 (s, 9H), 0.01 (s, 3H), −0.01 (s, 3H);
13C NMR (126 MHz, C6D6) δ 156.7, 140.5, 128.2, 120.9, 117.0, 96.5,
94.4, 78.0, 68.9, 66.5, 57.0, 55.5, 55.1, 54.4, 48.3, 46.8, 40.6, 37.8,
34.0, 26.1, 24.2, 18.4, 17.3, −5.3; IR (thin film) 2950, 2929, 2889,
2856, 2235, 1732, 1610, 1511, 1151, 1080, 1039, 833, 774 cm−1;
HRMS (ESI) m/z [M + Na]+ calc’d for C29H47NNaO6Si 556.3065,
found 556.3077.
Amide 8. MOM ether 12 (1.34 g, 2.51 mmol, 1.0 equiv) and
Rh(PPh3)3Cl (234.5 mg, 0.251 mmol, 10 mol %) were dissolved in
PhMe (5.0 mL, 0.5 M) in a round-bottomed flask. Acetaldoxime (3.8 mL,
62.8 mmol, 25 equiv) was sparged with N2 for 15 min, then added to the
flask, which was then fitted with a reflux condenser. The reaction
mixture was heated to 120 °C and held at this temperature for 14 h,
at which point it was allowed to cool to room temperature, mixed
with silica (10 mL), and concentrated carefully in vacuo. This mixture
was then loaded directly onto a column for purification. Purification
by column chromatography (eluting with 1−70% EtOAc/hexanes)
provided amide 8 as an amorphous white solid (974 mg, 1.77 mmol,
70% over 2 steps, 81% based on recovered 12). 1H NMR (500 MHz,
C6D6) δ 7.40 (d, J = 8.6 Hz, 2H), 7.09 (d, J = 8.5 Hz, 2H),
6.15 (bs, 1H), 6.13 (s, 1H), 4.86 (s, 2H), 4.37 (d, J = 6.4 Hz, 1H),
4.32 (d, J = 6.5 Hz, 1H), 4.16 (ddd, J = 10.7, 8.0, 2.3 Hz, 1H), 3.89
(d, J = 9.5 Hz, 1H), 3.66 (t, J = 2.9 Hz, 1H), 3.44 (d, J = 9.6 Hz, 1H),
3.43−3.36 (m, 1H), 3.40 (t, J = 7.1 Hz, 1H), 3.19 (s, 3H), 3.18
(s, 1H), 3.13 (s, 3H), 3.09 (s, 3H), 2.62 (ddd, J = 13.0, 8.2, 4.8 Hz,
1H), 2.52 (q, J = 12.1 Hz, 1H), 1.91 (ddq, J = 15.8, 7.1, 4.1 Hz, 1H),
1.77 (dq, J = 14.1, 2.9 Hz, 1H), 1.66 (ddd, J = 11.6, 6.9, 2.4 Hz, 1H),
1.47 (qd, J = 13.1, 3.4 Hz, 1H), 1.27 (ddd, J = 12.8, 6.4, 2.8 Hz, 1H),
1.16 (tt, J = 13.5, 2.7 Hz, 1H), 0.98 (s, 9H), 0.04 (s, 3H), 0.02
(s, 3H); 13C NMR (126 MHz, C6D6) δ 174.8, 156.2, 143.6, 128.6,
117.0, 96.6, 94.5, 77.4, 71.6, 66.9, 61.4, 56.6, 55.5, 55.2, 53.5, 45.4,
42.3, 38.2, 34.0, 26.2, 24.3, 18.5, 17.8, −5.27, −5.29; IR (thin film)
3500−3300, 2950, 2930, 2889, 2821, 1673, 1510, 1153, 1089, 836,
776 cm−1; HRMS (ESI) m/z [M + H]+ calc’d for C29H50NO7Si
552.3351, found 552.3360.
Alcohol 13. Amide 8 (719 mg, 1.30 mmol, 1.0 equiv) was dissolved
in MeCN (8.7 mL, 0.15 M) in a round-bottomed flask open to air.
PhI(OAc)2 (548 mg, 1.70 mmol, 1.3 equiv) was added and the
reaction mixture was stirred vigorously for 5 min, at which point KOH
(365 mg, 6.51 mmol, 5.0 equiv) was added as a solution in H2O
(4.3 mL, 0.30 M with respect to amide 8). The reaction mixture was
capped loosely and stirred at room temperature for 6 h. The resulting
pink-orange solution was diluted with H2O (5 mL) and concentrated
in vacuo to remove the MeCN. The aqueous material was extracted
with EtOAc (3 × 10 mL); then the combined organic extracts were
washed with brine (5 mL), dried over Na2SO4, filtered, and
concentrated in vacuo. Amine S6 was obtained as a pink oil, which
was then azeotropically dried with benzene (3 × 5 mL). Amine S6
was advanced without further purification.
Amine S6 (700 mg) was dissolved in CH2Cl2 (13 mL, 0.1 M), then
cooled in an ice/water bath. Pyridine (0.53 mL, 6.58 mmol, 5.0 equiv)
was added, followed by Ac2O (0.37 mL, 3.91 mmol, 3.0 equiv). Each
addition was performed dropwise over 5 min by syringe. The reaction
mixture was allowed to warm gradually to room temperature over 16 h,
at which time it was quenched with NaHCO3 (10 mL) and extracted
with CH2Cl2 (3 × 10 mL). The combined organic extracts were dried
over Na2SO4, filtered, and concentrated in vacuo to give acetamide S7
as an orange oil, which was advanced without further purification.
Acetamide S7 (740 mg, 1.31 mmol, 1.0 equiv) was dissolved in
THF (13 mL, 0.1 M) in a round-bottomed flask open to air. TBAF
solution (2.6 mL, 2.62 mmol, 2.0 equiv, 1 M in THF) was added and
the reaction mixture stirred for 15 h. The crude reaction mixture was
concentrated in vacuo to give a brown oil. Purification by column
chromatography (eluting with 5−55% acetone/CH2Cl2) provided
alcohol 13 (445 mg, 0.985 mmol, 75% over 3 steps) as a white gum.
1H NMR (500 MHz, C6D6, 343 K)* δ 7.33 (d, J = 8.4 Hz, 2H), 7.06
(d, J = 8.1 Hz, 2H), 5.42 (d, J = 10.1 Hz, 1H), 5.09 (t, J = 9.4 Hz,
1H), 4.88 (s, 2H), 4.76 (d, J = 6.5 Hz, 1H), 4.66 (d, J = 6.2 Hz, 1H),
3.42 (dd, J = 16.5, 10.0 Hz, 2H), 3.33 (s, 3H), 3.29 (d, J = 7.6 Hz,
1H), 3.24 (t, J = 8.5 Hz, 1H), 3.16 (s, 3H), 2.94 (bs, 1H), 2.91
(s, 3H), 2.69−2.57 (m, 1H), 2.33 (q, J = 12.6 Hz, 1H), 1.75 (d, J =
15.5 Hz, 1H), 1.62 (s, 3H), 1.56 (t, J = 10.7 Hz, 1H), 1.36−1.26
(m, 2H), 1.20 (t, J = 12.6 Hz, 1H), 1.06−0.95 (m, 1H); 13C NMR
(126 MHz, C6D6, 343 K) δ 168.2, 156.5, 140.9, 128.4, 117.1, 98.0,
95.0, 78.4, 70.4, 66.3, 62.6, 55.5, 55.4, 55.1, 52.5, 50.8, 38.7, 38.4,
33.0, 24.2, 23.2, 17.7; IR (thin film) 3375, 2932, 2889, 2824, 1651,
1509, 1232, 1150, 1044, 919, 830 cm−1; HRMS (ESI) m/z [M + Na]+
calc’d for C24H37NNaO7 474.2462, found 474.2451. *
1H NMR peaks
did not fully coalesce at 343 K, so peaks are reported for major
rotamer at that temperature.
Piperidine 14. Alcohol 13 (445 mg, 0.984 mmol, 1.0 equiv) was
dissolved in CH2Cl2 (10. mL, 0.1 M). Et3N (0.69 mL, 4.92 mmol,
5.0 equiv) was added via syringe, followed by MsCl (120 μL,
1.48 mmol, 1.5 equiv). The reaction mixture was stirred at room tem-
perature for 3.5 h, then quenched by the addition of brine (10 mL).
The solution was extracted with CH2Cl2 (3 × 10 mL) and the
combined organic extracts were dried over Na2SO4, filtered, and con-
centrated in vacuo to give mesylate S8 as a pale brown foam (530 mg),
which was advanced without further purification.
Mesylate S8 (530 mg, 0.984 mmol, 1.0 equiv) was dissolved in
DMF (10. mL, 0.1 M). KH (59.2 mg, 1.48 mmol, 1.5 equiv) was
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added and the reaction mixture was heated in an oil bath at 50 °C for
15 h. At this point, conversion was judged to be incomplete (by TLC and
LC−MS analysis) and additional KH (39.0 mg, 0.984 mmol, 1.0 equiv)
was added after allowing the reaction mixture to cool to room tempera-
ture. The reaction mixture was returned to the oil bath and heated at
50 °C for 2 h. The reaction mixture was cooled to room temperature,
diluted with brine (10 mL) and H2O (90 mL), and extracted with
EtOAc (3 × 25 mL). The combined organic extracts were washed
with brine (5 mL), dried over Na2SO4, filtered, and concentrated in
vacuo to give a yellow oil. Purification by column chromatography
(eluting with 45−70% acetone/CH2Cl2) provided piperidine 14 (366 mg,
0.844 mmol, 86% over 2 steps) as a white gum. 1H NMR (500 MHz,
C6D6, 343 K) δ 7.09−6.97 (m, 4H), 4.87 (d, J = 1.1 Hz, 2H), 4.54
(d, J = 14.3 Hz, 1H), 4.29 (s, 1H), 4.29−4.22 (m, 1H), 4.23 (s, 1H),
3.62 (dd, J = 10.2, 7.5 Hz, 1H), 3.36 (d, J = 9.7 Hz, 1H), 3.14 (dd, J =
17.0, 7.9 Hz, 1H), 3.14 (s, 3H), 3.08 (s, 3H), 3.05 (s, 3H), 3.02
(d, J = 9.7 Hz, 1H), 2.82 (dd, J = 14.5, 4.6 Hz, 1H), 2.27 (s, 3H), 2.26
(bs, 1H), 2.18 (dt, J = 13.2, 6.5 Hz, 1H), 1.84−1.78 (m, 1H), 1.73
(dd, J = 13.4, 9.8 Hz, 1H), 1.69−1.63 (m, 1H), 1.65−1.58 (m, 1H),
1.38 (t, J = 4.1 Hz, 1H), 1.26 (td, J = 14.1, 5.5 Hz, 1H); 13C NMR
(126 MHz, C6D6, 343 K) δ 167.2, 156.3, 137.5, 127.5, 116.9, 97.0,
95.0, 77.4, 66.5, 64.8, 56.6, 55.6, 55.1, 53.0, 47.5, 42.1, 41.1, 33.5,
33.0, 30.1, 24.3, 22.1; IR (thin film) 2923, 2897, 2863, 2818, 1631,
1511, 1422, 1016, 916, 513 cm−1; HRMS (ESI) m/z [M + Na]+ calc’d
for C24H35NNaO6 456.2357, found 456.2346.
Aldehyde 7. Piperidine 14 (79.0 mg, 0.182 mmol, 1.0 equiv) was
dissolved in THF (1.4 mL, 75 mM) in a round-bottomed flask left open
to air. A 6 N HCl aqueous solution (0.84 mL, 5.0 mmol, 28 equiv) was
added and the reaction mixture was stirred at room temperature for
28 h, at which point it was concentrated in vacuo to remove THF.
The aqueous phase was diluted with brine (5 mL) and extracted with
CH2Cl2 (3 × 5 mL). The combined organic extracts were dried over
Na2SO4, filtered, and concentrated in vacuo to give diol S9 a white
solid (52 mg, 0.151 mmol, 84% crude yield), which was advanced
without further purification. IR (thin film) 3288, 2966, 2930,
2818, 1609, 1515, 1452, 1264, 1105, 830 cm−1; HRMS (ESI) m/z
[M + Na]+ calc’d for C20H27NNaO4 368.1832, found 368.1825.
Diol S9 (52.0 mg, 0.151 mmol, 1.0 equiv) was suspended in
CH2Cl2 (4.0 mL, 37 mM). DMSO (75 μL, 1.05 mmol, 7.0 equiv) was
added and the resulting suspension was cooled in a dry ice/acetone
bath at −78 °C. Oxalyl chloride (26 μL, 0.303 mmol, 2.0 equiv) was
added dropwise and the reaction mixture was maintained at −78 °C
for 75 min. Et3N (210 μL, 1.51 mmol, 10. equiv) was then added via
syringe and the solution was maintained at −78 °C for 45 min. The
light yellow solution was removed from the bath and stirred at room
temperature for 1 h, at which point it was quenched with NH4Cl
(saturated aqueous, 15 mL) and brine (5 mL). Upon extraction with
CH2Cl2 (3 × 5 mL), the combined organic extracts were dried over
Na2SO4, filtered, and concentrated in vacuo. Purification by column
chromatography (eluting with 0−40% acetone/CH2Cl2) provided
aldehyde 7 (30.0 mg, 0.0874 mmol, 58%) as a colorless oil. 1H NMR
(700 MHz, C6D6)* δ 9.37 (s, 1H), 7.00 (d, J = 8.1 Hz, 2H), 6.82
(d, J = 8.4 Hz, 2H),4.93 (bs, 1H), 4.32 (d, J = 14.3 Hz, 1H), 3.53
(dd, J = 10.3, 6.8 Hz, 1H), 3.42 (dd, J = 9.9, 6.1 Hz, 1H), 3.21 (d, J =
1.5 Hz, 3H), 3.06 (dd, J = 14.4, 5.3 Hz, 1H), 2.56 (t, J = 4.9 Hz, 1H),
2.33 (d, J = 1.4 Hz, 3H), 2.21 (dt, J = 13.1, 6.3 Hz, 1H), 2.03 (td, J =
6.5, 3.4 Hz, 1H), 1.98 (dd, J = 14.3, 9.6 Hz, 1H), 1.92−1.89 (m, 1H),
1.86 (q, J = 5.2 Hz, 1H), 1.56−1.50 (m, 1H), 1.47 (qd, J = 12.3,
4.9 Hz, 1H); 13C NMR (176 MHz, C6D6) δ 206.9, 169.1, 154.9, 131.5,
128.8, 115.9, 80.4, 65.2, 62.2, 56.5, 47.6, 41.7, 41.4, 32.5, 30.8, 29.1, 24.1,
22.4; IR (thin film) 3252, 2958, 2934, 2856, 2358, 1717, 1613, 1591,
1514, 1450, 1260, 1090, 1027, 799 cm−1; HRMS (ESI) m/z [M + H]+
calc’d for C20H26NO4 344.1856, found 344.1855. *Rotameric mixture
(3:1 ratio of rotamers at 298 K); peaks reported for major rotamer.
Dienone 15. Aldehyde 7 (23.0 mg, 0.0670 mmol, 1.0 equiv) and
NaHCO3 (23.4 mg, 0.279 mmol, 4.0 equiv) were suspended in
MeOH (3.0 mL, 22 mM), then sonicated until dissolution was nearly
complete. The mixture was cooled in an ice/water bath at 0 °C before
PhI(OAc)2 (22.6 mg, 0.0702 mmol, 1.04 equiv) was added. The
reaction mixture was allowed to warm gradually to room temperature
over 3.5 h, at which point H2O (0.5 mL) was added and the mixture
concentrated in vacuo to remove MeOH. The resulting residue was
diluted with H2O (1.0 mL) and extracted with EtOAc (3 × 1 mL).
The combined organic extracts were washed with brine (0.5 mL),
dried over Na2SO4, filtered, and concentrated in vacuo. Purification by
preparatory TLC (eluting with 20−50% acetone/CH2Cl2) provided
dienone 15 (13.0 mg, 0.0348 mmol, 52%) as a colorless oil. 1H NMR
(600 MHz, C6D6)* δ 6.62 (dd, J = 10.4, 3.2 Hz, 1H), 6.56 (dd, J = 10.4,
3.2 Hz, 1H), 6.03 (dd, J = 10.4, 2.0 Hz, 1H), 5.98 (dd, J = 10.4, 2.0 Hz,
1H), 4.90 (s, 1H), 4.21 (d, J = 14.4 Hz, 1H), 4.16 (s, 1H), 3.27 (dd, J =
10.9, 7.0 Hz, 1H), 3.21 (s, 3H), 3.00 (s, 3H), 2.68 (dd, J = 13.7, 6.2 Hz,
1H), 2.14 (dd, J = 7.2, 4.7 Hz, 1H), 2.01 (s, 3H), 2.00−1.95 (m, 1H),
1.68−1.61 (m, 1H), 1.50 (dq, J = 13.3, 2.9 Hz, 1H), 1.40−1.33 (m, 2H),
1.23 (dt, J = 7.5, 3.3 Hz, 1H), 1.10 (t, J = 8.5 Hz, 2H); 13C NMR
(126 MHz, C6D6) δ 183.7, 168.2, 148.9, 147.6, 128.6, 128.5, 103.8,
78.4, 74.9, 58.1, 56.8, 56.3, 52.5, 48.9, 41.3, 37.6, 32.5, 29.6, 29.4,
24.1, 22.4; IR (thin film) 2932, 2828, 1720, 1671, 1629, 1450, 1378,
1251, 1194, 1135, 1090, 948 cm−1; HRMS (ESI) m/z [M + H]+
calc’d for C21H28NO5 374.1962, found 374.1942. *Rotameric mixture
(4:1 ratio of rotamers at 298 K); peaks reported for major rotamer.
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